Tirzepatide and Hair Loss: What New Research Reveals

The race to find effective GLP-1 medications for weight management has introduced a side effect that dermatologists are increasingly flagging: hair loss. A new observational study examining over 25,000 users of GLP-1 drugs has raised fresh concerns about tirzepatide, marketed as Zepbound and Mounjaro, suggesting it may trigger greater hair shedding than its competitor semaglutide (Wegovy, Ozempic). While the research remains unpublished in peer-reviewed journals, it adds to mounting clinical evidence that rapid weight loss from these medications can reshape the scalp in unwanted ways.

The Evidence: A Year-Long Comparison

Researchers tracked 12,863 people on tirzepatide and 12,863 on semaglutide throughout a 12-month period, none with prior diagnoses of alopecia. The findings revealed a clear gap: 4.2 percent of tirzepatide users developed hair loss compared to 2.88 percent of semaglutide users. By the six-month mark, the difference was already visible, with 1.55 percent of the tirzepatide group experiencing shedding versus 1.24 percent on semaglutide.

Weight Loss as a Control Variable

The research team adjusted their analysis to account for a critical variable: the fact that tirzepatide typically produces faster and more dramatic weight loss than semaglutide. When they matched participants based on actual weight reduction rather than medication type, the gap persisted. Among users who lost equivalent amounts of weight, 4.24 percent on tirzepatide developed alopecia compared to 3.33 percent on semaglutide. This distinction matters because it suggests the medication itself—not merely the speed of weight loss—may be driving the increased risk.

Gender and Vulnerability

Women showed particular susceptibility to medication-related hair loss. Nearly 5.5 percent of female tirzepatide users experienced alopecia during the study, whereas 3.6 percent of female semaglutide users reported the same. The gender disparity underscores how biological factors beyond simple weight reduction may compound the effect in women.

Venky Soundararajan, PhD, chief scientific officer at Nference and a co-author of the study, emphasized the significance of these numbers: “Both tirzepatide and semaglutide have been associated with alopecia during weight reduction, but it remained unknown whether this was simply a consequence of losing weight or whether the risk might differ between the two therapies. In our study, hair loss was uncommon overall, but it was a real signal and should not be brushed aside.”

Why Tirzepatide May Carry Greater Risk

Read also: Quitting Botox and Fillers: One Woman’s Year of Grief and Growth · FDA Panel Votes to Ease Peptide Restrictions—Here’s What Changes · Build a Dermatologist-Approved Skincare Routine From Scratch · Why Dermatologists Are Seeing More Warts and Molluscum This Summer

Receptor Differences and Their Impact

The distinction between these two GLP-1 medications lies in how they interact with the body at a molecular level. Semaglutide activates a single receptor known as glucagon-like peptide-1 (GLP-1). Tirzepatide, however, is what researchers call a “dual agonist,” meaning it binds to both the GLP-1 receptor and a second receptor called glucose-dependent insulinotropic polypeptide (GIP). This dual action amplifies its weight-loss effects but may carry unintended consequences for hair follicles.

Joshua Zeichner, MD, director of Cosmetic and Clinical Research in the Department of Dermatology at The Mount Sinai Hospital, points to evidence that GIP receptors are present within hair follicles themselves. “Since tirzepatide affects more than one receptor, it may have a greater impact on the body than just weight loss,” Dr. Zeichner explains. “GIP receptors have been identified in the hair follicles and, as the drug binds to these receptors, it may have an effect on the microenvironment surrounding the hair follicles, impacting their activity.”

Rapid Weight Loss as a Catalyst

Susan Massick, MD, a board-certified dermatologist at The Ohio State University Wexner Medical Center, notes that physicians have long understood the connection between accelerated weight reduction and telogen effluvium, a form of temporary hair loss. Both tirzepatide and semaglutide accelerate weight loss dramatically compared to diet and exercise alone, making this mechanism relevant to both drugs. However, the additional receptor activation in tirzepatide may compound this baseline effect.

Emerging Research: Broader Context

The tirzepatide-specific findings align with earlier investigations into GLP-1 medications and hair health. A study published in The BMJ in late July analyzed data from people using GLP-1s to manage type 2 diabetes against those on other diabetes medications. The researchers found that GLP-1 users faced a 37 percent higher risk of alopecia diagnosis compared to patients on SGLT-2 inhibitors (such as Jardiance and Farxiga) and a 68 percent higher risk compared to those on DPP-4 medications (including Januvia and Tradjenta).

A separate June study involving nearly 2.4 million GLP-1 users uncovered distinctions in how different drugs affected hair loss patterns. Users of semaglutide showed elevated risk for androgenetic alopecia, a hormone-driven form of hair loss, when compared to those on metformin. Tirzepatide users displayed what researchers termed a “borderline association” with telogen effluvium—the temporary shedding type—rather than the permanent androgenetic form.

Who Faces the Highest Risk

Hormonal Factors in Women

Women on tirzepatide who experienced hair loss were significantly more likely to report irregular menstrual cycles, hypothyroidism, and polycystic ovary syndrome (PCOS) than female users who did not lose hair. Soundararajan acknowledges the complexity: “These are associations, not proof that any of these conditions cause medication-associated hair loss, but they suggest that underlying hormonal or autoimmune susceptibility may matter alongside weight loss for women using tirzepatide.”

Confounding Variables

Dr. Massick cautions that observational studies have inherent limitations. “This study does not truly capture other confounding factors such as lifestyle, dietary intake, and other underlying medical conditions,” she notes. Nutritional deficiencies, stress levels, sleep patterns, and pre-existing thyroid dysfunction could all independently trigger shedding in people who happen to use tirzepatide, muddying the causality question.

Types of Hair Loss and Timeline

Understanding the form of hair loss matters for prognosis. Telogen effluvium—the type associated with physical or emotional shock, including rapid weight loss—typically reverses once the stressor ends. Hair follicles enter a resting phase prematurely but resume normal growth cycles when conditions stabilize. Androgenetic alopecia, by contrast, represents permanent miniaturization of hair follicles due to hormonal sensitivity and progresses over time.

The timeline in the study suggests that shedding manifests gradually, becoming most pronounced after the six-month mark. This lag aligns with how telogen effluvium develops—hairs shed two to three months after the triggering event, meaning shedding peaks weeks after the weight loss rate peaks.

Treatment and Management Strategies

For individuals already experiencing tirzepatide-related shedding, Dr. Zeichner outlines several evidence-backed interventions. Minoxidil (Rogaine), applied topically, stimulates growth phase entry and works for both temporary and permanent hair loss. Finasteride (Propecia) inhibits the enzyme that converts testosterone to DHT, the hormone driving androgenetic alopecia. Micronutrient supplementation—particularly zinc, iron, and biotin—supports hair health when deficiency is present. Red light therapy and platelet-rich plasma (PRP) injections represent additional options, though evidence strength varies.

Patience is essential if telogen effluvium is the diagnosis. Dr. Massick reassures patients: “If your hair loss is related to telogen effluvium, you will not go bald or lose all your hair, and your hair will likely grow back once your weight stabilizes.” She emphasizes maintaining adequate calorie intake and dietary variety during weight loss, as malnutrition accelerates shedding independent of medication.

When to Consult a Dermatologist

Dr. Zeichner recommends a proactive approach: if you are considering starting a GLP-1 medication, discuss hair and skin health with a dermatologist beforehand. Those already experiencing shedding while on tirzepatide or semaglutide should seek professional evaluation to rule out concurrent thyroid disease, nutrient deficiency, or other reversible causes.

Hair thinning has emerged as an expected—though not inevitable—side effect in patients, particularly women, using GLP-1 drugs. The decision to continue tirzepatide despite hair loss risk remains personal and should weigh the benefits of weight reduction against the psychological and physical impact of shedding. A dermatologist can help navigate this calculus and implement targeted interventions to minimize loss during treatment.